Austin, July 31, 2025 (GLOBE NEWSWIRE) -- Asthma Treatment Market Size & Growth Analysis:
According to SNS Insider, the Asthma Treatment Market was valued at USD 26.78 billion in 2024 and is projected to reach USD 36.36 billion by 2032, growing at a CAGR of 3.99% during the forecast period of 2025-2032.
The global asthma treatment market continues to grow steadily on account of the increasing asthma prevalence, rising use of biologics for severe asthma cases, and technological advancements in inhaler devices. Growing awareness, early diagnosis, and stronger clinical guidelines contribute to better treatment compliance.
Get Free Sample Report of the Asthma Treatment Market: https://www.snsinsider.com/sample-request/3387
The U.S. asthma treatment market was estimated at USD 8.18 billion in 2024 and is expected to reach USD 10.81 billion by 2032, at a CAGR of 3.64% during the forecast period of 2025-2032
The U.S. is the leading region for North America’s asthma drug market, since the U.S. has the majority of total asthma patients, high volume of clinical research, and highest penetration of advanced inhalers and biologic treatment options Investors and pharmaceutical companies focus primarily on the U.S. market due to its reimbursement policies, significant healthcare spending, and developed infrastructure that favors treatment access, and innovation.
Major Players Analysis Listed in this Report are:
- GlaxoSmithKline plc (GSK)
- AstraZeneca plc
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim GmbH
- Merck & Co. Inc.
- Roche Holding AG
- Cipla Ltd.
- Mylan N.V. (Viatris Inc.)
- Regeneron Pharmaceuticals Inc.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Orion Corporation
- Zambon S.p.A.
- Vectura Group plc
- Mundipharma International Limited
- Glenmark Pharmaceuticals Ltd.
- Amgen Inc. and other players.
Segment Insights
The Adult Segment of the Market Holds a Larger Share by Age Group in the Asthma Treatment Market
In 2024, the asthma treatment market in the adult segment emerged as the leading segment as adult patients are diagnosed at a higher rate, are more engaged in healthcare, and adhere to treatment the most. Adults are more likely to have moderate-severe asthma and need long-term controller and biologic therapies. Moreover, the rising incidence of adult-onset asthma and the increased availability of specialized care and insurance in developed countries have further augmented the industry’s share throughout the market.
Inhalers Segment is Leading the Asthma Treatment Market, By Route of Administration
The inhalers segment held the largest share of the asthma treatment market in 2024, with around 68.5% market share, owing to its inhibitive use, easy availability for acute and long-term management, and effectiveness. Inhaled medications—in the form of metered-dose inhalers (MDIs) and dry powder inhalers (DPIs)—are targeted directly into the lungs for rapid relief with less systemic exposure. They are the preferred drug delivery system by patients and physicians because of their easy-to-carry, easy-to-use, and guideline-associated properties.
Regional Outlook
North America Dominates Asthma Treatment Market, Asia Pacific to Witness Fastest Growth
North America held a major market share of the asthma treatment market with a 40.1% market share in 2024, owing to advanced healthcare infrastructure, high awareness of new treatment options, adoption of biologic therapies, and smart inhaler technologies at an early stage. Well-established reimbursement, high levels of asthma awareness, and key pharmaceutical companies already in the market are also preventing further growth.
The asthma treatment market is projected to experience the highest growth in the Asia Pacific region over the forecast year, driven by the increasing burden of asthma, urbanization, pollution, and allergen levels. Health bases, income growth, and insurance coverage increases in countries such as China, India, and Southeast Asia will contribute to increased diagnosis and treatment rates.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/3387
Asthma Treatment Market Segmentation
By Treatment Type
- Long-Term Control Medications
- Inhaled corticosteroids
- Long-acting beta agonists (LABAs)
- Leukotriene modifiers
- Theophylline
- Biologics (e.g., omalizumab, mepolizumab, benralizumab)
- Quick-Relief Medications (Rescue Medications)
- Short-acting beta agonists (SABAs)
- Anticholinergics
- Oral and intravenous corticosteroids
- Others
- Combination therapies
- Allergen immunotherapy
By Route of Administration
- Inhalers
- Metered-dose inhalers (MDIs)
- Dry powder inhalers (DPIs)
- Nebulizers
- Oral
- Injectable
By Medication Type
- Controller Medications
- Reliever Medications
- Preventive Medications
By Age Group
- Pediatric
- Adult
- Geriatric
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By End User
- Hospitals & Clinics
- Homecare
- Specialty Centers
USP (Unique Selling Proposition)
• Biomarker & Phenotype Stratification Mapping
Assists the client in aligning product positioning and targeting tactics to unique asthma phenotypes for further precision medicine potential.
• Market Access & Reimbursement Country Profiles
Labs maps out pricing, access, and coverage barriers across high-potential geographies, resulting in better go-to-market planning.
• Adoption Trends: Smart Inhaler Devices and Connected Devices
Evaluates developments in digital respiratory care and potential new partners, products, and investments.
• Late-Stage (Phase II and III) Pipeline & Trial Analytics for Asthma Therapies
Who can use the Competitor analysis report? To analyze the opportunities in the market for stakeholders by identifying the high-growth segments.
• Economics of Biologics vs Conventional Treatments Comparisons
Facilitates value proposition communication and payer interaction by measuring the clinical and economic benefit of advanced therapies.
Asthma Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | US$ 26.78 billion |
| Market Size by 2032 | US$ 36.36 billion |
| CAGR (2025–2032) | 3.99% |
| U.S. Market 2024 | USD 8.18 billion |
| U.S. Forecast by 2032 | USD 10.81 billion |
| Base Year | 2024 |
| Forecast Period | 2025–2032 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Buy the Full Asthma Treatment Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/3387
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
